Core Viewpoint - ImmunityBio, Inc. (NASDAQ:IBRX) is experiencing significant market attention, with discussions around its stock performance and potential investment opportunities highlighted during a recent show featuring Jim Cramer [1][3]. Group 1: Stock Performance - ImmunityBio has seen a substantial increase in stock value following a meeting with the FDA, prompting discussions about taking profits on the stock due to its significant run-up [3]. - A large block of ImmunityBio stock was noted, but there is uncertainty regarding its current status in the market, leading to cautious investment recommendations [1]. Group 2: Investment Considerations - While ImmunityBio is recognized for its potential as an investment, there are suggestions that certain AI stocks may offer better upside potential and lower downside risk compared to ImmunityBio [4].